In NSCLC, several SMGs such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and other less established oncoproteins have been verified to serve as targets in personalized treatment (Tan et al., 2015). This evidence concerns the gene EGFR and non-small cell lung carcinoma.